Shots:
- LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)
- As per the deal, Tanabe Pharma will receive up to $435M in upfront & near-term milestone payments together with potential downstream milestones and tiered royalties on net sales
- Dersimelagon’s NDA for EPP & XLP was submitted to the FDA in Jun 2026 & remains under review, with no regulatory approval to date
Ref: Businesswire | Image: LEO Pharma & Tanabe | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
